Phase 2 N=20 Study to Evaluate ARD-101 in Adults With Obesity
Obesity
Primary: Relative Change in Body Weight (%) — -0.33; 0.38 Percentage of body weight change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,032 Novel Experimental COVID-19 Therapies Affecting Host Response
COVID-19 · SARS-CoV-2 Infection · Coronavirus Infection
Primary: Oxygen Free Days Through Day 28. — 9.0; 11.3; 8.1; 10.5 Days
N/A N=774 'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor
HIV Infections
Primary: Number of Treatment-naïve Participants With Human Immunodeficiency Virus Ribonucleic Acid (HIV-RNA) Levels Less Than (<)50 Copies/Milliliter (c/mL) at 24 Weeks After 2DR…
Phase 4 N=80 Improving PET Image Quality and Quantification by Using Motion Correction, Parametric Imaging and MAP Reconstruction
Brain Imaging · Whole Body Imaging
Primary: Motion Correction — 57.4; 13.9 percentage of voxels
Phase 2 N=50 H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas
Diffuse Intrinsic Pontine Glioma · Glioma · Diffuse Midline Glioma, H3 K27M-Mutant
Primary: Percentage of Participants With Adverse Events (AE) Related to Treatment — 5.26; 0; 0; 21.0 percentage of participants
Phase 3 N=12 An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease
Primary Immunodeficiency Disease
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and Non-serious TEAEs — 12; 3; 12 Participants
Phase 3 N=162 Study to Assess Safety and Efficacy of Engensis in Painful Diabetic Peripheral Neuropathy
Diabetic Neuropathy, Painful
Primary: Efficacy of Engensis Compared to Placebo Painful Diabetic Peripheral Neuropathy in Feet and Lower Legs Comparing Average Daily Pain Score From Day 0 Visit to Day 180…
N/A N=48 Ageing and Acute Care Physicians' Performance
Ageing
Primary: CRM Performance During First Sim Scenario Assessed by Ottawa Global Rating Scale (GRS) — -0.299 Pearson correlation coefficient — p=0.039
N/A N=102 Videos for Advance Care Planning in Young Adults
Advanced Cancer
Primary: Increased Concordance Rate in Stated Goals of Care (Life-prolonging Medical Care, Selective Medical Care, or Comfort-focused Care) — 20; 15; 5; 10 Participants
N/A N=110 Clinical Study for the Evaluation of the Safety and Effectiveness of Use of a Poly-L Lactic Acid Injectable Filler for the Aesthetic Treatment of Nasolabial Folds
Wrinkle
Primary: Change From Baseline in the Nasolabial Folds Severity Score on the Wrinkle Severity Rating Scale (WSRS) 6 Months After Treatment — -0.3; -0.2; -0.1 score on a scale
N/A N=20 Acupuncture on Chemotherapy-induced Peripheral Neuropathy
Randomized Controlled Trial · Breast Cancer · Chemotherapy-induced Peripheral Neuropathy
Primary: The Average Pain Severity in the Brief Pain Inventory-Short Form(BPI-SF) — 3.10; 3.10; 1.72; 3.50 score on a scale
N/A N=74 Arcos Revision Stem: Evaluation of Clinical Performance
Osteoarthritis · Avascular Necrosis · Rheumatoid Arthritis
Primary: Survivorship — 74 Participants
N/A N=186 Symbiofilm Trial in Allergic Kids (SYMBIOFILM-TAK)
Common Cold · Allergy
Primary: AUC (Area Under Curve) of the Wisconsin Upper Respiratory Symptoms Survey for Kids (WURSS-K) During the 10-day Treatment Period — 36.56; 55.54 scores on WURSS-K scale*…
Phase 2 N=76 Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder.
Detrusor Underactivity · Overactive Bladder
Primary: Changes in the Mean BCI for Male From Baseline to Week 12 — 64.604; 61.339; 75.156; 60.513 Score on a scale — p=<0.001
N/A N=47 Scalable Digital Delivery of Evidence-based Training for Professionals to Maximize Treatment Rates of OUD in Families
Community Reinforcement And Family Training · Family Health · Substance-Related Disorders
Primary: Community Reinforcement And Family Training (CRAFT) Procedure Fidelity — 44.00; 52.75; 57.25 Score on a scale — p=0.0008